Back to Sites St. Jude Children's Research Hospital CRS Site Number 6501 Address St. Jude/UTHSC CRS 262 Danny Thomas Place Memphis, TN 38105-2794 United States of America IMPAACT Members at this Site Debra Livingston CAB Liaison Ronald Dallas Clinical Research Assistant Robbin Christensen Co-Investigator Judy Glenn Co-Investigator Jennifer Griffith Co-Investigator Nanna Howlett Co-Investigator Susannah Keck Co-Investigator Carla McKinley London Co-Investigator Lennie Lott Co-Investigator Donna S. Nance Co-Investigator Nina Sublette Co-Investigator Ryan Heine CRS Coordinator Jill Utech CRS Coordinator Patricia Flynn CRS Leader Marion Donohoe CRS Staff Christine Sinnock CRS Staff Stephen Spector CTU Principal Investigator Blanca Castillo DAIDS PO Wally Bitar Data Manager Aditya Gaur Investigator Nehali Patel Investigator Edwin M. Thorpe Investigator Sherri Flax Local Laboratory Terrence Geiger Local Laboratory Susan Carr Pharmacist of Record Katherine Knapp Principal Investigator Studies at this Site A5241: Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US DAIDS Number 10395 Research Area Antiretroviral Strategies Study Status Concluded A5257: Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers DAIDS Number 10670 Research Area Antiretroviral Strategies Study Status Participants Off Study and Primary Analysis Completed 1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded P1026S: PK in Pregnancy DAIDS Number 10040 Research Area Treatment Study Status Closed to Follow Up P1036A: Directly Observed Therapy in HIV-Infected Adolescents. DAIDS Number 10193 Research Area Other Study Status Concluded P1063: Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of Increased LDL-Cholesterol in HIV-Infected children, Adolescents, and Young Adults DAIDS Number 10167 Research Area Complications & Comorbidities Study Status Concluded P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded P1074: IMPAACT LTFU Study DAIDS Number 10660 Research Area Complications & Comorbidities Study Status Concluded P1076: Impact of Oral Alendronate Therapy on BMD in HIV-Infected Children/Adolescents DAIDS Number 10669 Research Area Complications & Comorbidities Study Status Concluded Pagination Current page 1 Page 2 Page 3 Next page Next
A5241: Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US DAIDS Number 10395 Research Area Antiretroviral Strategies Study Status Concluded
A5257: Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers DAIDS Number 10670 Research Area Antiretroviral Strategies Study Status Participants Off Study and Primary Analysis Completed
1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed
P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded
P1036A: Directly Observed Therapy in HIV-Infected Adolescents. DAIDS Number 10193 Research Area Other Study Status Concluded
P1063: Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of Increased LDL-Cholesterol in HIV-Infected children, Adolescents, and Young Adults DAIDS Number 10167 Research Area Complications & Comorbidities Study Status Concluded
P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded
P1074: IMPAACT LTFU Study DAIDS Number 10660 Research Area Complications & Comorbidities Study Status Concluded
P1076: Impact of Oral Alendronate Therapy on BMD in HIV-Infected Children/Adolescents DAIDS Number 10669 Research Area Complications & Comorbidities Study Status Concluded